JP6954744B2 - Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト - Google Patents

Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト Download PDF

Info

Publication number
JP6954744B2
JP6954744B2 JP2017017946A JP2017017946A JP6954744B2 JP 6954744 B2 JP6954744 B2 JP 6954744B2 JP 2017017946 A JP2017017946 A JP 2017017946A JP 2017017946 A JP2017017946 A JP 2017017946A JP 6954744 B2 JP6954744 B2 JP 6954744B2
Authority
JP
Japan
Prior art keywords
seq
indicated
cdr
region
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017017946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017184723A5 (enExample
JP2017184723A (ja
Inventor
トビアス ラウム
トビアス ラウム
マルクス ミュンツ
マルクス ミュンツ
ヨハネス ブロジー
ヨハネス ブロジー
ピーター クファー
ピーター クファー
パトリック ホフマン
パトリック ホフマン
マチアス フリードリヒ
マチアス フリードリヒ
ベノ ラテル
ベノ ラテル
パメラ ボグナー
パメラ ボグナー
アンドレアス ウォルフ
アンドレアス ウォルフ
コーネリアス ポンペ
コーネリアス ポンペ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of JP2017184723A publication Critical patent/JP2017184723A/ja
Publication of JP2017184723A5 publication Critical patent/JP2017184723A5/ja
Priority to JP2021160762A priority Critical patent/JP7295916B2/ja
Application granted granted Critical
Publication of JP6954744B2 publication Critical patent/JP6954744B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017017946A 2016-02-03 2017-02-02 Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト Active JP6954744B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021160762A JP7295916B2 (ja) 2016-02-03 2021-09-30 Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290875P 2016-02-03 2016-02-03
US62/290,875 2016-02-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021160762A Division JP7295916B2 (ja) 2016-02-03 2021-09-30 Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト

Publications (3)

Publication Number Publication Date
JP2017184723A JP2017184723A (ja) 2017-10-12
JP2017184723A5 JP2017184723A5 (enExample) 2020-03-05
JP6954744B2 true JP6954744B2 (ja) 2021-10-27

Family

ID=57984927

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017017946A Active JP6954744B2 (ja) 2016-02-03 2017-02-02 Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
JP2021160762A Active JP7295916B2 (ja) 2016-02-03 2021-09-30 Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021160762A Active JP7295916B2 (ja) 2016-02-03 2021-09-30 Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト

Country Status (32)

Country Link
US (3) US10781264B2 (enExample)
EP (2) EP4206228A1 (enExample)
JP (2) JP6954744B2 (enExample)
KR (1) KR102845959B1 (enExample)
CN (2) CN114716557A (enExample)
AR (1) AR107582A1 (enExample)
AU (1) AU2017216237B2 (enExample)
CA (1) CA3011942A1 (enExample)
CL (1) CL2018002063A1 (enExample)
CO (1) CO2018008722A2 (enExample)
CR (1) CR20180418A (enExample)
DK (1) DK3411404T3 (enExample)
EA (1) EA201891753A1 (enExample)
ES (1) ES2935419T3 (enExample)
FI (1) FI3411404T3 (enExample)
HU (1) HUE060504T2 (enExample)
IL (1) IL260920B (enExample)
LT (1) LT3411404T (enExample)
MA (1) MA43959A (enExample)
MX (1) MX2018009386A (enExample)
MY (1) MY195542A (enExample)
PH (1) PH12018501558A1 (enExample)
PL (1) PL3411404T3 (enExample)
PT (1) PT3411404T (enExample)
SG (2) SG11201806150RA (enExample)
SI (1) SI3411404T1 (enExample)
TN (1) TN2018000266A1 (enExample)
TW (1) TWI767899B (enExample)
UA (1) UA126656C2 (enExample)
UY (1) UY37105A (enExample)
WO (1) WO2017134158A1 (enExample)
ZA (1) ZA201804829B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022020636A (ja) * 2016-02-03 2022-02-01 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2356153T3 (en) * 2008-10-01 2016-07-04 Amgen Res Munich Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2016016859A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
CU24597B1 (es) 2014-11-26 2022-05-11 Xencor Inc Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
KR102688969B1 (ko) 2016-02-03 2024-07-30 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
JOP20190189A1 (ar) * 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
CN111406068A (zh) 2017-05-16 2020-07-10 约翰霍普金斯大学 MANAbody及使用方法
KR102414120B1 (ko) 2017-08-03 2022-06-28 암젠 인크 인터류킨-21 뮤테인 및 치료 방법
ES2985118T3 (es) 2017-09-08 2024-11-04 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
CN111727197A (zh) 2018-01-12 2020-09-29 美国安进公司 抗pd-1抗体和治疗方法
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
BR112020023872A2 (pt) 2018-05-24 2021-02-17 Janssen Biotech, Inc. agentes de ligação de psma e seus usos
EA202190955A1 (ru) * 2018-10-01 2021-08-17 Эмджен Инк. Способы снижения агрегации биспецифических антител
KR20220002899A (ko) 2019-04-19 2022-01-07 얀센 바이오테크 인코포레이티드 항-psma/cd3 항체로 전립선암을 치료하는 방법
MA56120A (fr) * 2019-06-07 2022-04-13 Amgen Inc Constructions de liaison bispécifiques
US20220372148A1 (en) 2019-07-05 2022-11-24 Ono Pharmaceutical Co., Ltd. A pharmaceutical composition for treating hematological cancer
AU2020320420A1 (en) * 2019-07-26 2022-03-17 Ixaka France Aptamer-based multispecific therapeutic agents
EP3842461A1 (en) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4196163A4 (en) * 2020-08-14 2024-08-28 Chugai Seiyaku Kabushiki Kaisha ONE-ARM ANTIGEN-BINDING MOLECULES AND THEIR USES
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
MX2023003041A (es) 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
EP4228694A4 (en) * 2020-10-15 2024-12-18 Janux Therapeutics, Inc. ANTIBODIES DIRECTED AGAINST PSMA AND CD3 AND USES THEREOF
MX2023006817A (es) * 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
AR124448A1 (es) * 2020-12-22 2023-03-29 Amgen Inc Ensayo de gradiente de difusión para moléculas que contienen anti-cd3
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
WO2022232199A1 (en) 2021-04-28 2022-11-03 Amgen Inc. Systems for out-patient treatment of a patient, and related methods
JP2024517701A (ja) 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 組換え生産タンパク質の低分子量種を低減させる方法
KR20240015093A (ko) 2021-05-27 2024-02-02 사노피 Fc 수용체에 대한 향상된 친화성 및 개선된 열 안정성을 갖는 Fc 변이체
CN118574855A (zh) 2022-02-07 2024-08-30 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
CA3253777A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Polytherapeutic methods with T-lymphocyte-activating molecules for treating prostate cancer
JP2025528212A (ja) * 2022-08-18 2025-08-26 イムノコア リミテッド 複数ドメイン結合性分子
KR20250089544A (ko) 2022-11-24 2025-06-18 우시 바이올로직스 아일랜드 리미티드 Psma 항체 및 그의 용도
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識する二重特異性抗体
WO2025122824A1 (en) * 2023-12-08 2025-06-12 Nutcracker Therapeutics, Inc. Multivalent antibody constructs for targeting prostate cancer cells
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US556A (en) 1838-01-09 Machine foe
US5013A (en) 1847-03-13 Improvement in apparatus for the manufacture of malleable iron
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3850753T2 (de) 1987-12-09 1995-03-16 Omron Tateisi Electronics Co Induktives Datenübertragungssystem.
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AU4541093A (en) 1992-06-18 1994-01-24 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
CZ307995A3 (en) 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
WO1997007671A1 (en) 1995-08-29 1997-03-06 Kirin Beer Kabushiki Kaisha Chimeric animal and method for constructing the same
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
JP3795533B2 (ja) 1996-12-12 2006-07-12 プロルーム・リミテツド 感染性物質を検出及び同定するための方法及び装置
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
US6232107B1 (en) 1998-03-27 2001-05-15 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
US7254167B2 (en) 1998-10-30 2007-08-07 Broadcom Corporation Constellation-multiplexed transmitter and receiver
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
WO2003047336A2 (en) 2001-11-30 2003-06-12 Abgenix, Inc. TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
US8486859B2 (en) 2002-05-15 2013-07-16 Bioenergy, Inc. Use of ribose to enhance plant growth
US7904068B2 (en) 2003-06-06 2011-03-08 At&T Intellectual Property I, L.P. System and method for providing integrated voice and data services utilizing wired cordless access with unlicensed spectrum and wired access with licensed spectrum
IN2012DN00313A (enExample) 2003-06-27 2015-05-08 Amgen Fremont Inc
CA2540703C (en) 2003-10-03 2014-04-08 Board Of Regents, University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
SI1673398T1 (sl) 2003-10-16 2011-05-31 Micromet Ag Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP2228698B1 (en) 2005-03-14 2012-06-27 Omron Corporation Programmable controller system
CN101217979A (zh) 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂
US8234145B2 (en) 2005-07-12 2012-07-31 International Business Machines Corporation Automatic computation of validation metrics for global logistics processes
BRPI0604215A (pt) 2005-08-17 2007-04-10 Biosigma Sa método para projetar oligonucleotìdeos para técnicas de biologia molecular
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
JP2007122396A (ja) 2005-10-27 2007-05-17 Hitachi Ltd ディスクアレイ装置及びその障害対応検証方法
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US7919297B2 (en) 2006-02-21 2011-04-05 Cornell Research Foundation, Inc. Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase
US7574748B2 (en) 2006-03-07 2009-08-18 Nike, Inc. Glove with support system
US7990860B2 (en) 2006-06-16 2011-08-02 Harris Corporation Method and system for rule-based sequencing for QoS
US8430938B1 (en) 2006-07-13 2013-04-30 The United States Of America As Represented By The Secretary Of The Navy Control algorithm for autothermal reformer
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
KR101146588B1 (ko) 2006-08-11 2012-05-16 삼성전자주식회사 Ｆｉｎ 구조체 및 이를 이용한 핀 트랜지스터의 제조방법
CN100589507C (zh) 2006-10-30 2010-02-10 华为技术有限公司 一种拨号提示系统及方法
US7466008B2 (en) 2007-03-13 2008-12-16 Taiwan Semiconductor Manufacturing Company, Ltd. BiCMOS performance enhancement by mechanical uniaxial strain and methods of manufacture
EP2142533B1 (en) 2007-03-30 2011-11-16 F. Hoffmann-La Roche AG Imidazolidinone derivatives
EP3461842A1 (en) * 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Cross-species-specific binding domain
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2158318A2 (en) * 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
US8209741B2 (en) 2007-09-17 2012-06-26 Microsoft Corporation Human performance in human interactive proofs using partial credit
US8464584B2 (en) 2007-10-19 2013-06-18 Food Equipment Technologies Company, Inc. Beverage dispenser with level measuring apparatus and display
CN101883933B (zh) 2007-11-29 2014-04-23 舍弗勒技术股份两合公司 尤其是用于在驱动机与从动部分之间传递功率的力传递装置
US8376279B2 (en) 2008-01-23 2013-02-19 Aurora Flight Sciences Corporation Inflatable folding wings for a very high altitude aircraft
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
DK2356153T3 (en) 2008-10-01 2016-07-04 Amgen Res Munich Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
WO2010045261A1 (en) 2008-10-13 2010-04-22 Zymogenetics, Llc Single chain fc type iii interferons and methods of using same
US8311684B2 (en) 2008-12-17 2012-11-13 Pratt & Whitney Canada Corp. Output flow control in load compressor
JP4956801B2 (ja) 2009-03-04 2012-06-20 日産自動車株式会社 排気ガス浄化触媒及びその製造方法
HUE029619T4 (en) 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
US8463191B2 (en) 2009-04-02 2013-06-11 Qualcomm Incorporated Beamforming options with partial channel knowledge
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
US9023996B2 (en) 2009-12-23 2015-05-05 Synimmune Gmbh Anti-FLT3 antibodies
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN103347893A (zh) 2010-11-01 2013-10-09 诺维信生物制药丹麦公司 白蛋白变体
MY173177A (en) 2010-11-10 2020-01-02 Amgen Res Munich Gmbh Prevention of adverse effects caused by cd3 specific binding domains
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
PL2647707T3 (pl) 2010-11-30 2019-02-28 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny wywołujący cytotoksyczność
CA2819269A1 (en) 2010-12-20 2012-06-28 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
CN103298648B (zh) 2010-12-30 2016-04-13 C.劳勃.汉默斯坦两合有限公司 适于机动车辆座椅的包括两对导轨的纵向调节装置
US8822417B2 (en) 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
BR112014003769B1 (pt) 2011-08-23 2022-05-10 Roche Glycart Ag Molécula de ligação ao antígeno biespecífica ativadora de célula t, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CL2014001263A1 (es) 2011-11-15 2014-10-10 Boehringer Ingelheim Int Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
SG11201402365RA (en) 2011-11-16 2014-06-27 Amgen Inc Methods of treating epidermal growth factor deletion mutant viii related disorders
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US9718893B2 (en) 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
US20150037334A1 (en) 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
CA2876133C (en) 2012-06-07 2017-06-06 Duke University Human bispecific egfrviii antibody engaging molecules
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
RU2650868C2 (ru) 2012-07-13 2018-04-17 Займворкс Инк. Биспецифические асимметричные гетеродимеры, содержащие анти-cd3 конструкции
AU2013306076B2 (en) 2012-08-21 2018-01-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
WO2014100490A1 (en) 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2014122144A1 (en) 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
PT2961771T (pt) 2013-02-26 2020-02-28 Roche Glycart Ag Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea
CN105705519A (zh) * 2013-03-06 2016-06-22 梅里麦克制药股份有限公司 抗C-MET串联Fc双特异性抗体
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
AR095596A1 (es) 2013-03-15 2015-10-28 Amgen Res Munich Gmbh Moléculas de unión de cadena única comprendiendo n-terminal abp
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP2970484B2 (en) 2013-03-15 2022-09-21 Amgen Inc. Heterodimeric bispecific antibodies
WO2015006482A1 (en) 2013-07-09 2015-01-15 Duke University CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
RU2696892C2 (ru) 2013-08-07 2019-08-07 Аффимед Гмбх САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3842455A1 (en) 2014-01-15 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with improved protein a-binding
KR20230022270A (ko) 2014-03-28 2023-02-14 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
BR112016027888A2 (pt) 2014-05-28 2017-10-24 Zymeworks Inc construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
WO2016016859A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
AR101400A1 (es) 2014-07-31 2016-12-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
FI3608337T3 (fi) 2014-08-04 2024-06-13 Hoffmann La Roche Bispesifisiä t-solua aktivoivia antigeenia sitovia molekyylejä
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements
US20170247476A1 (en) 2014-09-25 2017-08-31 Amgen Inc. Protease-activatable bispecific proteins
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CU24597B1 (es) 2014-11-26 2022-05-11 Xencor Inc Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
CN104829726B (zh) 2015-01-21 2019-03-05 武汉友芝友生物制药有限公司 一种双特异性抗体cd19xcd3的构建及应用
CN104829728B (zh) 2015-01-21 2019-03-12 武汉友芝友生物制药有限公司 一种双特异性抗体her2xcd3的构建及应用
TN2017000275A1 (en) 2015-01-23 2018-10-19 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016123675A1 (en) 2015-02-05 2016-08-11 The University Of Queensland Targeting constructs for delivery of payloads
CA2982682A1 (en) 2015-04-17 2016-10-20 Amgen Research (Munich) Gmbh Bispecific antibody constructs for cdh3 and cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
UA127515C2 (uk) 2015-08-17 2023-09-20 Янссен Байотек, Інк. Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання
JP2018534933A (ja) 2015-11-02 2018-11-29 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用
US9552854B1 (en) 2015-11-10 2017-01-24 Intel Corporation Register files including distributed capacitor circuit blocks
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
US10781264B2 (en) * 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
KR102688969B1 (ko) 2016-02-03 2024-07-30 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
IL295509A (en) 2016-09-23 2022-10-01 Regeneron Pharma Steap2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Compounds That Bind Steap2 and CD3, and Their Uses
IL265309B2 (en) 2016-09-23 2024-04-01 Regeneron Pharma Bispecific anti-muc16 antibodies and anti-muc16 antibodies for use in treating cancer
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
BR112019022751A2 (pt) 2017-05-05 2020-05-19 Amgen Inc composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022020636A (ja) * 2016-02-03 2022-02-01 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
JP7295916B2 (ja) 2016-02-03 2023-06-21 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト

Also Published As

Publication number Publication date
BR112018015415A2 (en) 2018-12-18
EP4206228A1 (en) 2023-07-05
US20250333537A1 (en) 2025-10-30
CN114716557A (zh) 2022-07-08
TN2018000266A1 (en) 2020-01-16
US20170218079A1 (en) 2017-08-03
CO2018008722A2 (es) 2018-08-31
CR20180418A (es) 2019-01-15
EP3411404B1 (en) 2022-11-09
PT3411404T (pt) 2023-01-02
EA201891753A1 (ru) 2019-01-31
MA43959A (fr) 2018-12-12
PL3411404T3 (pl) 2023-02-13
US12428491B2 (en) 2025-09-30
SG11201806150RA (en) 2018-08-30
LT3411404T (lt) 2022-12-27
ZA201804829B (en) 2023-10-25
US10781264B2 (en) 2020-09-22
FI3411404T3 (fi) 2023-01-31
JP2017184723A (ja) 2017-10-12
JP2022020636A (ja) 2022-02-01
US20210070878A1 (en) 2021-03-11
EP3411404A1 (en) 2018-12-12
TWI767899B (zh) 2022-06-21
CN109311979A (zh) 2019-02-05
IL260920B (en) 2022-09-01
IL260920A (enExample) 2018-09-20
AU2017216237A1 (en) 2018-08-09
DK3411404T3 (da) 2023-01-30
MX2018009386A (es) 2018-11-09
SG10202007331WA (en) 2020-09-29
TW201730215A (zh) 2017-09-01
SI3411404T1 (sl) 2023-01-31
ES2935419T3 (es) 2023-03-06
HUE060504T2 (hu) 2023-03-28
UY37105A (es) 2017-09-29
AU2017216237B2 (en) 2024-04-04
KR102845959B1 (ko) 2025-08-18
UA126656C2 (uk) 2023-01-11
KR20180101623A (ko) 2018-09-12
PH12018501558A1 (en) 2019-05-20
WO2017134158A1 (en) 2017-08-10
AR107582A1 (es) 2018-05-16
HK1257749A1 (en) 2019-10-25
JP7295916B2 (ja) 2023-06-21
CA3011942A1 (en) 2017-08-10
MY195542A (en) 2023-01-31
CL2018002063A1 (es) 2018-11-23

Similar Documents

Publication Publication Date Title
JP6954744B2 (ja) Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
JP7478762B2 (ja) 二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
JP6959011B2 (ja) Ｂｃｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
US20250368737A1 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
KR102700015B1 (ko) 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
JP7026610B2 (ja) メソテリン及びｃｄ３に結合する二重特異性抗体構築物
JP2021508465A (ja) Ｍｕｃ１７及びｃｄ３に向けられる二重特異性抗体コンストラクト
JP2022512636A (ja) 二重特異性抗体コンストラクトの下流プロセシング
JP2025533434A (ja) 二重特異性分子安定化組成物
EA043696B1 (ru) Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
EA043309B1 (ru) Биспецифические конструкции антител, вовлекающие т-клетки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210930

R150 Certificate of patent or registration of utility model

Ref document number: 6954744

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250